Variable | Chart view HR (95% CI) | P-value | High-accuracy HR (95% CI) | P-value | High-PPV HR (95% CI) | P-value | High-sensitivity HR (95% CI) | P-value | |
---|---|---|---|---|---|---|---|---|---|
Age (year) | < = 35 | Reference | 0.124 | Reference | 0.123 | Reference | 0.125 | Reference | 0.162 |
36–40 | 1.51 (0.89–2.57) | 1.62 (0.92–2.84) | 1.42 (0.78–2.57) | 1.39 (0.85–2.27) | |||||
41–55 | 0.92 (0.51–1.66) | 0.87 (0.47–1.6) | 0.83 (0.44–1.6) | 0.75 (0.44–1.29) | |||||
> = 56 | 0.66 (0.33–1.32) | 0.7 (0.35–1.4) | 0.53 (0.25–1.16) | 0.72 (0.4–1.31) | |||||
Tumor stage* | 0-I | Reference | < 0.0001 | Reference | < 0.0001 | Reference | < 0.0001 | Reference | < 0.0001 |
II | 1.83 (0.82–4.06) | 2.92 (1.08–7.91) | 1.84 (0.71–4.78) | 2.3 (1.09–4.87) | |||||
III | 7.19 (3.24–15.92) | 11.83 (4.38–31.91) | 8.62 (3.37–22.03) | 8.19 (3.85–17.43) | |||||
ER status | Negative | Reference | 0.622 | Reference | 0.181 | Reference | 0.397 | Reference | 0.229 |
Positive | 0.87 (0.5–1.52) | 0.69 (0.41–1.19) | 0.77 (0.43–1.4) | 0.74 (0.45–1.21) | |||||
PR status | Negative | Reference | 0.199 | Reference | 0.074 | Reference | 0.672 | Reference | 0.31 |
Positive | 0.71 (0.43–1.19) | 0.63 (0.38–1.05) | 0.89 (0.51–1.55) | 0.79 (0.49–1.25) | |||||
HER2 status* | Negative | Reference | 0.003 | Reference | 0.003 | Reference | 0.007 | Reference | 0.016 |
Positive | 0.48 (0.3–0.77) | 0.48 (0.3–0.77) | 0.5 (0.3–0.83) | 0.6 (0.4–0.91) | |||||
Histology | Ductal | Reference | 0.182 | Reference | 0.058 | Reference | 0.102 | Reference | 0.102 |
Lobular | 0.52 (0.2–1.36) | 0.9 (0.37–2.2) | 0.97 (0.39–2.43) | 0.57 (0.24–1.38) | |||||
Other | 1.51 (0.75–3.01) | 2.17 (1.13–4.17) | 2.16 (1.06–4.41) | 1.67 (0.9–3.08) | |||||
Tumor grade | 1 | Reference | 0.379 | Reference | 0.052 | Reference | 0.065 | Reference | 0.101 |
2 | 1.92 (0.75–4.93) | 2.19 (0.76–6.3) | 1.68 (0.58–4.88) | 1.83 (0.77–4.38) | |||||
3 | 1.92 (0.75–4.93) | 3.12 (1.0–8.86) | 2.66 (0.93–7.63) | 2.38 (0.99–5.66) | |||||
Hormone therapy* | No | Reference | 0.013 | Reference | 0.002 | Reference | 0.016 | Reference | 0.05 |
Yes | 0.74 (0.4–1.36) | 1.22 (0.64–2.36) | 0.84 (0.42–1.67) | 0.99 (0.57–1.72) | |||||
Unknown | 3.65 (1.35–9.81) | 5.14 (2.06–12.83) | 4.34 (1.47–12.79) | 2.72 (1.16–6.35) | |||||
Radiotherapy* | No | Reference | 0.017 | Reference | 0.002 | Reference | 0.030 | Reference | 0.058 |
Yes | 1.01 (0.55–1.87) | 1.03 (0.55–1.96) | 0.88 (0.44–1.75) | 0.97 (0.56–1.69) | |||||
Unknown | 0.25 (0.1–0.66) | 0.22 (0.09–0.52) | 0.24 (0.09–0.7) | 0.38 (0.17–0.85) | |||||
Chemotherapy | No | Reference | 0.158 | Reference | 0.216 | Reference | 0.258 | Reference | 0.001 |
Yes | 0.57 (0.27–1.24) | 0.57 (0.24–1.38) | 0.59 (0.24–1.47) | 0.33 (0.17–0.63)^ | |||||
Year of diagnosis | 2007–2009 | Reference | 0.784 | Reference | 0.228 | Reference | 0.394 | Reference | 0.188 |
2010–2012 | 1.29 (0.63–2.63) | 1.7 (0.82–3.52) | 1.07 (0.48–2.39) | 1.78 (0.96–3.31) | |||||
2013–2015 | 1.27 (0.56–2.88) | 2.07 (0.9–4.75) | 1.55 (0.63–3.79) | 1.71 (0.83–3.54) |